{"title":"Metabolic \u0026 Weight Research","description":"\u003cp dir=\"auto\"\u003eMaster metabolic science and body composition research with \u003cstrong\u003eQuickPenPro Metabolic \u0026amp; Weight Research\u003c\/strong\u003e peptides.\u003c\/p\u003e\n\u003cp dir=\"auto\"\u003eThis focused collection features premium research-grade peptides studied for their effects on fat metabolism, lipolysis, energy expenditure, insulin sensitivity, and weight regulation. Delivered in QuickPenPro’s precise, easy-to-use pen format, these compounds support laboratories exploring obesity models, visceral fat reduction, mitochondrial function, and long-term metabolic health.\u003c\/p\u003e","products":[{"product_id":"cjc-1295-no-dac","title":"CJC-1295 No DAC 10mg","description":"\u003cp\u003eCJC-1295 no DAC is a modified GHRH analog used in research on pulsatile growth hormone release and pituitary signaling.\u003c\/p\u003e\n\u003cp\u003eCJC-1295 without DAC is a tetrasubstituted GHRH analog designed for enhanced receptor affinity and predictable pulsatile GH release. Unlike the DAC version, this form has a shorter half-life and is therefore used in models that require dynamic GH pulse frequency rather than sustained elevation. Researchers frequently explore its impact on IGF-1 regulation, pituitary responsiveness, and hypothalamic-pituitary communication.\u003c\/p\u003e\n\u003cdiv data-widget_type=\"heading.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"70108bd\" class=\"elementor-element elementor-element-70108bd elementor-widget elementor-widget-heading\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003ePen Dosage Chart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"a2c1f5a\" class=\"elementor-element elementor-element-a2c1f5a color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003ctable style=\"width: 100%;\" cellpadding=\"10\" cellspacing=\"0\" border=\"1\"\u003e\n\u003ccolgroup\u003e \u003ccol style=\"width: 21.033868%;\" width=\"50%\"\u003e \u003ccol style=\"width: 78.787879%;\" width=\"50%\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eCJC-1295 No DAC 10mg QuickPen Pro\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003e3.0 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emg\/mL\u003c\/td\u003e\n\u003ctd\u003e3.33 mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClick-to-Dose\u003c\/td\u003e\n\u003ctd\u003e1 click = 0.033 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample(s)\u003c\/td\u003e\n\u003ctd\u003e30 clicks(10 of Pen Scale) = 1 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp data-end=\"839\" data-start=\"425\"\u003e \u003c\/p\u003e\n\u003cdiv data-widget_type=\"heading.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"3839bb6\" class=\"elementor-element elementor-element-3839bb6 elementor-widget elementor-widget-heading\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eBenefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"a88a59d\" class=\"elementor-element elementor-element-a88a59d color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eEnhances natural pulsatile growth hormone secretion:\u003c\/b\u003e\u003cbr\u003eCJC-1295 (No DAC) amplifies endogenous growth hormone release by directly stimulating the GHRH receptor pathway in the anterior pituitary. Growth hormone is physiologically secreted in discrete pulses, with peak amplitude occurring during deep sleep phases. Rather than producing continuous elevation, CJC-1295 increases the magnitude of these pulses while preserving their rhythmic nature. This pulsatile enhancement is central to maintaining receptor sensitivity and preventing desensitization associated with sustained hormone exposure. The short-acting profile allows GH levels to rise and fall within natural regulatory parameters.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSelective engagement of the GHRH receptor cascade:\u003c\/b\u003e\u003cbr\u003eCJC-1295 (No DAC) binds specifically to the growth hormone–releasing hormone receptor (GHRH-R), a G-protein–coupled receptor expressed on somatotroph cells. Activation of this receptor increases adenylate cyclase activity, elevating intracellular cAMP levels. This rise in cAMP activates protein kinase A, leading to enhanced transcription and exocytosis of growth hormone. Unlike ghrelin-based peptides that act through the GHS-R1a receptor, CJC-1295 does not directly stimulate appetite-related hypothalamic pathways. This receptor specificity differentiates it mechanistically from GHRP compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePreserves hypothalamic somatostatin regulation:\u003c\/b\u003e\u003cbr\u003eThe hypothalamus tightly controls GH release through a balance between GHRH stimulation and somatostatin inhibition. Because CJC-1295 stimulates endogenous pathways rather than bypassing them, somatostatin feedback remains active. This allows the body to modulate hormone output dynamically based on physiologic demand. Maintaining this inhibitory counterbalance is important in experimental models examining long-term endocrine stability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSupports downstream IGF-1–mediated anabolic signaling:\u003c\/b\u003e\u003cbr\u003eOnce growth hormone is released, it stimulates hepatic production of insulin-like growth factor 1 (IGF-1). IGF-1 activates intracellular pathways including PI3K\/Akt and mTOR, which regulate protein synthesis and cellular growth. Through this two-step endocrine cascade, CJC-1295 indirectly influences tissue adaptation and recovery-related signaling. This layered activation preserves physiological hierarchy rather than directly activating peripheral receptors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eShort-acting profile enables pulse timing studies:\u003c\/b\u003e\u003cbr\u003eUnlike the DAC-modified formulation, the No DAC version lacks albumin-binding extension and therefore has a shorter half-life. This transient activity allows researchers to evaluate timing-dependent endocrine responses and synchronization with circadian cycles. Pulse timing plays a critical role in how tissues respond to growth hormone exposure. By aligning with physiologic rhythms, CJC-1295 (No DAC) supports research focused on hormone pattern optimization rather than continuous stimulation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eInfluences sleep-associated growth hormone peaks:\u003c\/b\u003e\u003cbr\u003eGrowth hormone secretion is closely linked to slow-wave sleep. Amplifying physiologic GH pulses may enhance the magnitude of nocturnal hormone peaks in experimental models. This connection places CJC-1295 within integrated sleep–endocrine research frameworks. Rather than inducing sleep directly, it operates within hormonal cycles that coincide with restorative phases.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eDistinct from ghrelin mimetics and appetite-driven peptides:\u003c\/b\u003e\u003cbr\u003eGHRP compounds stimulate growth hormone release via ghrelin receptor activation and may influence hunger pathways. CJC-1295 operates exclusively through the GHRH receptor pathway, avoiding direct activation of neuropeptide Y–mediated appetite signaling. This distinction makes it more focused on pituitary modulation than hypothalamic hunger circuits. The absence of strong appetite stimulation differentiates its systemic profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFacilitates structured endocrine modulation research:\u003c\/b\u003e\u003cbr\u003eBecause it enhances natural hormone pulses rather than replacing GH, CJC-1295 supports investigation into physiologic endocrine adaptation. The preservation of feedback loops, receptor sensitivity, and pulse rhythm allows researchers to examine nuanced hormonal modulation. This precision positions the No DAC variant within rhythm-aligned growth hormone research rather than sustained supraphysiologic exposure models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIntegrates within broader neuroendocrine coordination networks:\u003c\/b\u003e\u003cbr\u003eGrowth hormone interacts with metabolic regulation, connective tissue remodeling, and circadian timing systems. By amplifying endogenous GH pulses, CJC-1295 participates in this integrated neuroendocrine network. Its activity reflects coordinated communication between hypothalamus, pituitary, and peripheral tissues. This systems-level positioning differentiates it from peptides that act directly at peripheral receptors without upstream regulatory integration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"Default Title","offer_id":57221836505465,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/cjc-1295-no-dac-10mg-9483367.png?v=1778161513"},{"product_id":"tesamorelin","title":"Tesamorelin","description":"\u003cp\u003eTesamorelin is a stabilized peptide analog of GHRH used in growth hormone axis and metabolic research.\u003c\/p\u003e\n\u003cp\u003eTesamorelin is a synthetic Growth Hormone–Releasing Hormone (GHRH) analog with enhanced stability due to its trans-3-hexenoic acid modification. It exhibits high affinity for GHRH receptors in the pituitary, leading to robust GH signaling in research environments. Studies often explore its impact on IGF-1 modulation, visceral fat mobilization pathways, and endocrine function. Tesamorelin is valued for its predictable pharmacological behavior and extended half-life compared to native GHRH.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"10mg","offer_id":57222235554169,"sku":null,"price":100.0,"currency_code":"EUR","in_stock":true},{"title":"20mg","offer_id":57222235586937,"sku":null,"price":183.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/tesamorelin-8470631.png?v=1778161512"},{"product_id":"ipamorelin","title":"Ipamorelin","description":"\u003cp\u003eIpamorelin is a selective pentapeptide used in research focused on growth hormone secretion pathways.\u003c\/p\u003e\n\u003cp\u003eIpamorelin is a highly selective growth hormone secretagogue that binds to the ghrelin receptor (GHSR-1a). Research frequently examines its ability to stimulate pulsatile GH release without significantly influencing cortisol, prolactin, or ACTH pathways. Its clean selectivity profile makes it useful for models studying appetite signaling, metabolic balance, and pituitary function. Ipamorelin is widely used due to its consistent receptor specificity and minimal off-target interaction.\u003c\/p\u003e\n\u003cp\u003eResearch on ipamorelin extends to gastrointestinal motility, where studies report that it accelerates gastric emptying and colonic transit time in post-operative ileus models. Published work in the Journal of Surgical Research describes ipamorelin's prokinetic effects in rodent models of bowel surgery, suggesting a mechanism related to ghrelin receptor activation in the enteric nervous system. This application is distinct from its growth hormone-releasing activity.\u003c\/p\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"Default Title","offer_id":57221865374073,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/ipamorelin-3023006.png?v=1778161514"},{"product_id":"retatrutide-glp-3r","title":"Reta GLP-3R","description":"\u003cp\u003eReta is an investigational tri-agonist peptide studied for its interaction with three key receptor systems: GLP-1, GIP, and GCGR (glucagon). In research settings, it is examined for its ability to engage these pathways simultaneously, allowing scientists to explore multi-receptor activity within metabolic experimental models.\u003c\/p\u003e\n\u003cp\u003eReta activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor. GLP-1 receptor activation promotes insulin secretion, reduces appetite, and slows gastric emptying. GIP receptor activation enhances the incretin effect on beta cells and may influence adipose tissue metabolism. Glucagon receptor activation increases hepatic glucose output and energy expenditure. The combination of all three agonist activities in a single molecule distinguishes GLP-3 R from dual-agonist compounds.\u003c\/p\u003e\n\u003cdiv class=\"elementor-element elementor-element-70108bd elementor-widget elementor-widget-heading\" data-id=\"70108bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003ePen Dosage Chart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-a2c1f5a color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"a2c1f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\" style=\"width: 100%;\"\u003e\n\u003ccolgroup\u003e \u003ccol width=\"50%\" style=\"width: 21.033868%;\"\u003e \u003ccol width=\"50%\" style=\"width: 78.787879%;\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eReta GLP-3R 12mg QuickPen Pro\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003e3.0 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emg\/mL\u003c\/td\u003e\n\u003ctd\u003e4 mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClick-to-Dose\u003c\/td\u003e\n\u003ctd\u003e1 click = 0.04 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample(s)\u003c\/td\u003e\n\u003ctd\u003e30 clicks(10 of Pen Scale) = 1.2 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"425\" data-end=\"839\"\u003e \u003c\/p\u003e\n\u003cdiv data-widget_type=\"heading.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"461454e\" class=\"elementor-element elementor-element-461454e elementor-widget elementor-widget-heading\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eMechanism of Action\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"89ab6a4\" class=\"elementor-element elementor-element-89ab6a4 color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003cp\u003eAs a unimolecular agonist, Rеtаtrutіdе binds to GLP-1R, GIPR, and GCGR with high affinity, leading to cAMP-mediated signaling cascades that enhance pancreatic beta-cell insulin release, suppress glucagon in hyperglycemia, and increase hepatic fatty acid oxidation. In animal models, this results in upregulated thermogenesis via UCP1 in brown adipose tissue and reduced lipogenesis. In vitro studies confirm synergistic receptor crosstalk, amplifying AMPK activation for improved mitochondrial function and reduced inflammation markers like CRP.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"menu-anchor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"bf2e85c\" class=\"elementor-element elementor-element-bf2e85c elementor-widget elementor-widget-menu-anchor\"\u003e\n\u003cdiv id=\"3\" class=\"elementor-menu-anchor\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"heading.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"3839bb6\" class=\"elementor-element elementor-element-3839bb6 elementor-widget elementor-widget-heading\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003eBenefits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv data-widget_type=\"text-editor.default\" data-e-type=\"widget\" data-element_type=\"widget\" data-id=\"a88a59d\" class=\"elementor-element elementor-element-a88a59d color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\"\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eTriple Agonist Mechanism for Comprehensive Metabolic Regulation\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе is a potent \u003cb\u003eGLP-1, GIP, and glucagon receptor agonist\u003c\/b\u003e, studied for its multi-pathway activation of energy metabolism. By engaging all three receptors, it enhances insulin secretion, suppresses appetite, and promotes lipid oxidation simultaneously. This triple agonist design provides broader metabolic modulation than single or dual incretin analogs, making it a leading subject in next-generation obesity and diabetes research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eExceptional Weight Reduction Outcomes\u003c\/b\u003e:\u003cbr\u003eClinical and preclinical data show that Rеtаtrutіdе can produce \u003cb\u003eup to 24% body weight reduction\u003c\/b\u003e over extended treatment periods. This outcome surpasses previous GLP-1 or GLP-1\/GIP agonists due to enhanced thermogenesis and fat oxidation mechanisms. Research indicates a sustained and progressive decline in both subcutaneous and visceral fat mass, positioning Rеtаtrutіdе as a new benchmark in metabolic optimization studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eMarked Reduction in Visceral and Hepatic Fat\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе has been observed to dramatically \u003cb\u003ereduce liver fat content\u003c\/b\u003e (over 80% in clinical data) and visceral adiposity in both obese and type 2 diabetic subjects. This effect stems from its ability to activate glucagon receptor-mediated lipid metabolism and enhance mitochondrial β-oxidation, promoting improved liver function and systemic metabolic balance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImprovement in Glucose Control and Insulin Sensitivity\u003c\/b\u003e:\u003cbr\u003eThrough simultaneous activation of incretin pathways, Rеtаtrutіdе enhances \u003cb\u003einsulin secretion\u003c\/b\u003e, suppresses glucagon, and improves peripheral glucose uptake. This coordinated metabolic effect results in significant HbA1c reduction and stabilization of fasting glucose levels in research subjects. These findings highlight its potential as one of the most effective glucose-lowering peptides under investigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eEnhanced Lipid Profile and Cardiovascular Markers\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе administration has been associated with improved \u003cb\u003elipid metabolism\u003c\/b\u003e, including reductions in total cholesterol, LDL, and triglycerides. Studies also report lower systolic blood pressure and inflammatory markers such as CRP, suggesting favorable cardiometabolic outcomes in long-term metabolic studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStimulation of Energy Expenditure and Thermogenesis\u003c\/b\u003e:\u003cbr\u003eIn animal models, Rеtаtrutіdе increases \u003cb\u003ethermogenic activity\u003c\/b\u003e in brown adipose tissue via glucagon receptor signaling, leading to higher resting energy expenditure. Enhanced mitochondrial respiration and fatty acid oxidation contribute to continuous fat loss even under moderate caloric intake, establishing its potential as a metabolic rate enhancer in research applications.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eReduction of Systemic Inflammation\u003c\/b\u003e:\u003cbr\u003eRеtаtrutіdе has been observed to \u003cb\u003ereduce inflammatory cytokines\u003c\/b\u003e such as TNF-α and IL-6, while improving endothelial function and vascular elasticity. These anti-inflammatory and vasoprotective effects complement its metabolic actions, promoting improved cardiovascular resilience in experimental models of metabolic disease.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePreservation of Lean Body Mass\u003c\/b\u003e:\u003cbr\u003eResearch findings suggest that despite substantial fat loss, Rеtаtrutіdе supports the \u003cb\u003emaintenance of lean muscle tissue\u003c\/b\u003e. This balance between adipose reduction and muscle preservation reflects its unique energy-partitioning effect, making it valuable for studies exploring body recomposition and athletic performance enhancement.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eLiver Function and NAFLD Improvement\u003c\/b\u003e:\u003cbr\u003ePreclinical and early clinical studies show significant improvements in \u003cb\u003enon-alcoholic fatty liver disease (NAFLD)\u003c\/b\u003e parameters, including reduced hepatic inflammation and fibrosis. Rеtаtrutіdе’s triple-agonist activation enhances AMPK signaling, reducing lipid accumulation and promoting hepatic regeneration in metabolic liver research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSynergistic Effects with GLP-1 and Mitochondrial Peptides\u003c\/b\u003e:\u003cbr\u003eExperimental protocols combining Rеtаtrutіdе with \u003cstrong\u003eS\u003c\/strong\u003e\u003cstrong\u003eеmаglutіdе\u003c\/strong\u003e\u003cb\u003e, MOTS-c, or SS-31\u003c\/b\u003e are being explored to enhance mitochondrial bioenergetics, lipid metabolism, and overall metabolic performance. These stacked combinations aim to maximize fat oxidation, reduce inflammation, and sustain high energy efficiency in long-term research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eLong-Term Metabolic Adaptation and Weight Maintenance\u003c\/b\u003e:\u003cbr\u003eFollow-up studies indicate that subjects maintained over \u003cb\u003e80% of their weight loss\u003c\/b\u003e after extended observation periods, even after discontinuation. This sustained adaptation reflects durable improvements in metabolic set-point, appetite control, and mitochondrial efficiency, marking Rеtаtrutіdе as a highly promising agent for advanced metabolic research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStandard Research Protocol\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDose: 2 – 4 mg weekly, titrate to 12 mg\u003c\/li\u003e\n\u003cli\u003eDuration: 20 – 48 weeks\u003c\/li\u003e\n\u003cli\u003eFrequency: 1× weekly\u003c\/li\u003e\n\u003cli\u003eCycle Interval: 20 – 48 weeks on, 4 – 8 weeks off, then reassess\u003c\/li\u003e\n\u003cli\u003eGoal \/ Description: Gradual weight reduction, improved glycemic markers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eGlucose-Focus Protocol\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDose: 0.25 – 1.0 mg weekly\u003c\/li\u003e\n\u003cli\u003eDuration: 8 – 10 weeks\u003c\/li\u003e\n\u003cli\u003eFrequency: 1× weekly\u003c\/li\u003e\n\u003cli\u003eCycle Interval: 8 – 10 weeks on, 4 weeks off\u003c\/li\u003e\n\u003cli\u003eGoal \/ Description: Improved fasting\/postprandial control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"12mg","offer_id":57222187614585,"sku":null,"price":209.0,"currency_code":"EUR","in_stock":true},{"title":"20mg","offer_id":57222187647353,"sku":null,"price":280.0,"currency_code":"EUR","in_stock":true},{"title":"30mg","offer_id":57222187680121,"sku":null,"price":336.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/reta-glp-3r-7025321.png?v=1778161511"},{"product_id":"hgh-fragment-176-191","title":"HGH Fragment 176-191 10mg","description":"\u003cp\u003eHGH Fragment 176-191 (AOD-9604) corresponds to the C-terminal 16–amino-acid region of human growth hormone. In experimental models it is used to investigate GH-fragment signaling, lipolytic pathways in adipocytes and metabolic regulation, while avoiding direct activation of full-length GH receptor mitogenic pathways. All studies remain strictly within laboratory\/experimental contexts without therapeutic claims.\u003c\/p\u003e\n\u003cdiv class=\"elementor-element elementor-element-70108bd elementor-widget elementor-widget-heading\" data-id=\"70108bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003ePen Dosage Chart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-a2c1f5a color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"a2c1f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\" style=\"width: 100%;\"\u003e\n\u003ccolgroup\u003e \u003ccol width=\"50%\" style=\"width: 21.033868%;\"\u003e \u003ccol width=\"50%\" style=\"width: 78.787879%;\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eHGH Fragment 176-191 10mg QuickPen Pro\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003e3.0 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emg\/mL\u003c\/td\u003e\n\u003ctd\u003e3.33 mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClick-to-Dose\u003c\/td\u003e\n\u003ctd\u003e1 click = 0.033 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample(s)\u003c\/td\u003e\n\u003ctd\u003e30 clicks(10 of Pen Scale) = 1 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"425\" data-end=\"839\"\u003e \u003c\/p\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"Default Title","offer_id":57221939790201,"sku":null,"price":90.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/hgh-fragment-176-191-10mg-7962454.png?v=1778161514"},{"product_id":"ipa-cjc-ipamorelin-cjc-1257-10-10mg","title":"IPA + CJC Blend (Ipamorelin + CJC-1295) 10\/10mg","description":"\u003ch2 data-section-id=\"rmw5tv\" data-start=\"0\" data-end=\"14\"\u003eDescription\u003c\/h2\u003e\n\u003cp\u003eQuickPen Pro IPA+CJC Blend (Ipamorelin 10mg + CJC-1295 10mg)\u003c\/p\u003e\n\u003cp data-start=\"16\" data-end=\"301\"\u003eThis advanced growth hormone support peptide formulation combines Ipamorelin 10mg and CJC-1295 10mg into a unified endocrine and recovery optimization blend designed for research involving growth hormone signaling, recovery physiology, metabolic regulation, and healthy aging pathways.\u003c\/p\u003e\n\u003cp data-start=\"303\" data-end=\"718\"\u003eIpamorelin is a selective growth hormone secretagogue studied for its ability to stimulate pulsatile growth hormone release through ghrelin receptor activation while maintaining a highly selective signaling profile. CJC-1295 is a long-acting growth hormone releasing hormone (GHRH) analog investigated for prolonged stimulation of endogenous growth hormone and IGF-1 pathways through pituitary signaling modulation.\u003c\/p\u003e\n\u003cp data-start=\"720\" data-end=\"1175\"\u003eTogether, this blend is positioned within experimental frameworks examining synergistic support of physiological growth hormone pulsatility, recovery dynamics, tissue regeneration signaling, sleep-associated anabolic activity, and metabolic resilience. Rather than functioning as direct exogenous hormone replacement, the peptide complex is investigated for its role in supporting endogenous endocrine rhythm optimization and adaptive recovery mechanisms.\u003c\/p\u003e\n\u003cp data-start=\"1177\" data-end=\"1397\"\u003eResearch domains include recovery physiology, lean tissue signaling, metabolic efficiency, sleep-related growth hormone dynamics, exercise recovery, body composition research, and longevity-associated endocrine pathways.\u003c\/p\u003e\n\u003cp data-start=\"1399\" data-end=\"1841\"\u003eOur formulation is provided in a stabilized pre-mixed injection pen for SubQ administration. Subcutaneous delivery supports consistent systemic exposure and reliable peptide absorption in research protocols. Each unit is freshly prepared to preserve peptide integrity and ensure standardized dosing. This format eliminates multi-step reconstitution and simplifies laboratory handling. The product is formulated strictly for research use only.\u003c\/p\u003e\n\u003cdiv class=\"elementor-element elementor-element-70108bd elementor-widget elementor-widget-heading\" data-id=\"70108bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\"\u003e\n\u003ch3 class=\"elementor-heading-title elementor-size-default\"\u003ePen Dosage Chart\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"elementor-element elementor-element-a2c1f5a color-scheme-inherit text-left elementor-widget elementor-widget-text-editor\" data-id=\"a2c1f5a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\"\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"10\"\u003e\n\u003ccolgroup\u003e \u003ccol width=\"50%\"\u003e \u003ccol width=\"50%\"\u003e \u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\"\u003e\u003cstrong\u003eQuickPen Pro IPA+CJC Blend (Ipamorelin 10mg + CJC-1295 10mg) \u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003e3.0 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emg\/mL\u003c\/td\u003e\n\u003ctd\u003e3.33 mg\/mL of each peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClick-to-Dose\u003c\/td\u003e\n\u003ctd\u003e1 click = 0.033 mg of each peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample(s)\u003c\/td\u003e\n\u003ctd\u003e30 clicks(10 of Pen Scale) = 1 mg of each peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003chr data-start=\"1843\" data-end=\"1846\"\u003e\n\u003ch2 data-section-id=\"1v31agu\" data-start=\"1848\" data-end=\"1866\"\u003eClinical Status\u003c\/h2\u003e\n\u003cp data-start=\"1868\" data-end=\"1921\"\u003eHuman RCT ▣ | Observational ✔ | Animal ✔ | In vitro ✔\u003c\/p\u003e\n\u003cp data-start=\"1923\" data-end=\"2071\"\u003ePrimarily studied in endocrine, metabolic, and recovery-focused research settings, with expanding investigation in growth hormone modulation models.\u003c\/p\u003e\n\u003chr data-start=\"2073\" data-end=\"2076\"\u003e\n\u003ch2 data-section-id=\"uz8gfd\" data-start=\"2078\" data-end=\"2100\"\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp data-start=\"2102\" data-end=\"2742\"\u003eThis peptide blend is studied for its combined influence on endogenous growth hormone secretion and downstream anabolic signaling pathways. Ipamorelin selectively activates ghrelin (GHS-R1a) receptors involved in pulsatile growth hormone release while minimizing activity on cortisol and prolactin pathways in experimental systems. CJC-1295 functions as a growth hormone releasing hormone analog that prolongs pituitary stimulation and supports sustained growth hormone signaling. Together, these mechanisms may enhance physiological GH pulse amplitude, IGF-1 activity, recovery signaling, and metabolic regulation in research environments.\u003c\/p\u003e\n\u003chr data-start=\"2744\" data-end=\"2747\"\u003e\n\u003ch1 data-section-id=\"b8y6te\" data-start=\"2749\" data-end=\"2759\"\u003eBenefits\u003c\/h1\u003e\n\u003ch3 data-section-id=\"1il0918\" data-start=\"2761\" data-end=\"2811\"\u003eSupports Endogenous Growth Hormone Pulsatility\u003c\/h3\u003e\n\u003cp data-start=\"2813\" data-end=\"3118\"\u003eIpamorelin and CJC-1295 are extensively studied for their complementary activity in supporting physiological growth hormone release patterns. Experimental models examine how synchronized GHRH and ghrelin receptor signaling may optimize pulsatile GH dynamics and downstream anabolic communication pathways.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1qdzw54\" data-start=\"3120\" data-end=\"3177\"\u003eExamined In Recovery And Regenerative Research Models\u003c\/h3\u003e\n\u003cp data-start=\"3179\" data-end=\"3460\"\u003eGrowth hormone signaling plays a central role in tissue recovery, cellular repair, and adaptive regeneration. Research involving this blend explores recovery-supportive pathways associated with muscle repair, connective tissue resilience, and post-stress physiological restoration.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1nvibgv\" data-start=\"3462\" data-end=\"3512\"\u003eSupports IGF-1 And Anabolic Signaling Pathways\u003c\/h3\u003e\n\u003cp data-start=\"3514\" data-end=\"3827\"\u003eCJC-1295-mediated stimulation of endogenous growth hormone release contributes to downstream IGF-1 signaling activity. Combined with Ipamorelin-associated GH pulse amplification, the blend is studied within anabolic signaling frameworks involving tissue maintenance, recovery physiology, and metabolic adaptation.\u003c\/p\u003e\n\u003ch3 data-section-id=\"1k9hwq5\" data-start=\"3829\" data-end=\"3876\"\u003eSupports Sleep-Associated Recovery Dynamics\u003c\/h3\u003e\n\u003cp data-start=\"3878\" data-end=\"4207\"\u003eGrowth hormone release is closely linked to deep sleep physiology and nocturnal recovery processes. Experimental systems involving Ipamorelin examine interactions between GH pulsatility and sleep-related restorative signaling pathways. These mechanisms position the blend within integrated recovery and sleep-regulation research.\u003c\/p\u003e\n\u003ch3 data-section-id=\"zjzc07\" data-start=\"4209\" data-end=\"4266\"\u003eExamined In Lean Tissue And Body Composition Research\u003c\/h3\u003e\n\u003cp data-start=\"4268\" data-end=\"4571\"\u003eResearch involving growth hormone secretagogues frequently explores pathways associated with lean tissue maintenance, metabolic efficiency, and nutrient partitioning. Experimental models evaluate how optimization of endogenous GH signaling may influence body composition dynamics and energy utilization.\u003c\/p\u003e\n\u003ch3 data-section-id=\"z5pcfr\" data-start=\"4573\" data-end=\"4625\"\u003eSupports Metabolic Regulation And Energy Balance\u003c\/h3\u003e\n\u003cp data-start=\"4627\" data-end=\"4935\"\u003eGrowth hormone and IGF-1 signaling influence lipid metabolism, glucose utilization, and energy regulation pathways. Studies involving Ipamorelin and CJC-1295 examine how peptide-mediated endocrine modulation may support metabolic flexibility and adaptive energy balance under physiological stress conditions.\u003c\/p\u003e\n\u003ch3 data-section-id=\"14pc75e\" data-start=\"4937\" data-end=\"5013\"\u003eDistinct Regulatory Profile Compared To Exogenous Hormone Administration\u003c\/h3\u003e\n\u003cp data-start=\"5015\" data-end=\"5344\"\u003eUnlike direct growth hormone replacement strategies, this peptide blend is investigated for stimulation of endogenous hormonal rhythms through physiological signaling pathways. Research focuses on supporting natural endocrine communication and pulsatile hormone release dynamics rather than continuous exogenous hormone exposure.\u003c\/p\u003e\n\u003ch3 data-section-id=\"bjf6mk\" data-start=\"5346\" data-end=\"5412\"\u003eSupports Exercise Recovery And Performance Physiology Research\u003c\/h3\u003e\n\u003cp data-start=\"5414\" data-end=\"5692\"\u003eExperimental models involving physical stress and intensive training examine how enhanced growth hormone signaling may influence recovery capacity, tissue adaptation, and muscular resilience. This blend is studied within broader performance and recovery optimization frameworks.\u003c\/p\u003e\n\u003ch3 data-section-id=\"n9wyh\" data-start=\"5694\" data-end=\"5756\"\u003eIntegrated Endocrine–Recovery–Longevity Research Framework\u003c\/h3\u003e\n\u003cp data-start=\"5758\" data-end=\"6152\" data-is-last-node=\"\" data-is-only-node=\"\"\u003eGrowth hormone signaling, recovery physiology, metabolic regulation, and healthy aging are deeply interconnected biological systems. The Ipamorelin + CJC-1295 blend is studied within integrated research models examining how optimization of endogenous anabolic signaling pathways may influence long-term recovery efficiency, tissue resilience, metabolic stability, and physiological performance.\u003c\/p\u003e","brand":"Quickpen Pro Peptides","offers":[{"title":"Default Title","offer_id":57346297692537,"sku":null,"price":159.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/files\/ipa-cjc-blend-ipamorelin-cjc-1295-1010mg-4729651.png?v=1780122490"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0999\/0776\/4601\/collections\/metabolic-weight-research-8972896.png?v=1778081339","url":"https:\/\/www.quickpen.pro\/collections\/metabolic-weight-research.oembed","provider":"Quickpen Pro Peptides","version":"1.0","type":"link"}